Month: June 2024

Belships has declared a purchase option for BELMAR, which has been leased since its delivery as a newbuilding in 2021. The purchase price is USD 25.5m and the vessel will be taken over in Q4 2024. The acquisition will be financed from the company’s available cash. Furthermore, Belships has agreed to acquire a Japanese-built Ultramax of 64 000 dwt built in 2024 from an unrelated party. The purchase price is USD 41.0m and the vessel will be delivered within Q1 2025. The intention is to utilise our available Accordian Tranche which implies financing for 60 per cent of the purchase price and the remaining will be financed from the company’s available cash. The sale of the two Supramax vessels BELFRIEND and BELTIDE announced previously are expected to be handed over to their new owners within Q3 2024. As the vessels are free of debt the sales...

Meriaura Group Plc Company Announcement            26 June 2024 at 2.00 p.m. (CEST)Meriaura Group Plc – Managers’ Transaction, Jussi Mälkiä, June 2024   Person subject to the notification requirementName: Meriaura Invest Oy  Position: Closely associated person(x) Legal Person (1): Associated PersonName Mälkiä, Jussi-PekkaPosition Member of the Board/Deputy member  Initial Notification  Reference number: 67381/4/4     IssuerName: Meriaura Group PlcLEI: 743700J1YZ8IEJAPDL21     Transaction detailsTransaction date: 2024-06-25Venue: Outside a trading venueNature of the transaction: ACQUISITIONFurther details:   Instrument: SHAREISIN: FI4000425848 (1) Volume: 6800000Unit price: 0.05882 EUR(2) Volume: 6800000Unit price: 0.05882 EUR Aggregated transactionsVolume: 13600000Volume...

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023. This patent covers novel crystalline forms of buntanetap and their use for treating and/or preventing various neurodegenerative conditions. Crystalline forms offer significant advantages over less structured forms, including better solubility and stability. The most stable crystal form of buntanetap (CAS# 3032752-92-1)...

Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU). ACTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study investigating the role of interleukin-6 (IL-6) in patients diagnosed with sepsis and septic shock. This prospective study assessed the utility of IL-6 upon initial presentation to the intensive care unit (ICU). The primary analysis of the SYMON-I study (registered clinical trial number NCT06181604) highlighted that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU may...

Newly Launched ProFound Cloud Delivers Radiologists Cost-Effective, Secure, and Scalable Access to iCAD’s Breast Health Suite of AI Solutions NASHUA, N.H., June 26, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, today announced it will highlight new research demonstrating the efficacy of its ProFound AI Risk algorithm in breast cancer risk assessment compared to traditional models at the upcoming Society for Imaging Informatics in Medicine (SIIM) Annual Meeting. The company will also highlight its recently launched ProFound Cloud, an advanced software-as-a-service (SaaS) platform that offers medical providers a cost-effective, secure, and scalable solution for accessing and deploying the latest ProFound Breast Health Suite of AI solutions. Mark Traill,...

VANCOUVER, British Columbia, June 26, 2024 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its scientific collaborators, Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University’s Department of Neuroscience (Ottawa, Canada), will present data from a study investigating the mechanisms of BETR-001 (2-bromo-LSD) at the upcoming FENS conference on June 25-29 in Vienna, Austria. BETR-001 is a non-hallucinogenic derivative of LSD, proprietary to BetterLife (patent pending). The study is titled “Cortical transcriptomic effects of the non-hallucinogenic 2-Bromo-LSD”. Dr. Lewis will present preclinical gene sequencing...

That being said, a majority of executives surveyed hold a positive view of AI, with 64% expressing optimism about the new technologyLayoffs Hit 50% of Finance Companies SurveyedTo help executives understand, react, and adapt to the ongoing challenges within the finance industry, Fiverr has released a new report, Strategic Insights: Leveraging Freelance Talent in Finance.NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) — To help executives understand, react, and adapt to the ongoing challenges within the finance industry, Fiverr (NYSE: FVRR) has released a new report, Strategic Insights: Leveraging Freelance Talent in Finance. The report dives into pain points in the sector, including in which quarter leaders feel the most stressed (the second quarter) and offers insight into how executives in the sector are adapting to and overcoming...

Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced members of VYNE’s management will participate in one-on-one meetings at the Leerink Partners Therapeutics Forum on Immunology and Inflammation (I&I) and Metabolic Diseases on Tuesday, July 9, 2024. About VYNE Therapeutics Inc.VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain &...

NAPLES, Fla., June 26, 2024 (GLOBE NEWSWIRE) — HealthLynked Corp. (OTCQB: HLYK), a pioneering provider of healthcare technology solutions, is pleased to announce the promotion of Bill Crupi to the position of Chief Operating Officer (COO), effective immediately. This strategic appointment underscores HealthLynked’s commitment to operational excellence and its vision to enhance healthcare connectivity. Bill Crupi joined HealthLynked in 2023 and has since been instrumental in optimizing operational efficiencies and supporting the company’s growth trajectory. With over two decades of experience in the healthcare sector, Bill has demonstrated exceptional leadership in operations management and has been a driving force in advancing HealthLynked’s mission to connect patients and healthcare providers through innovative...

6th International Navy to Select LRAD 950NXTs for Long-Range Communication and Scalable Escalation of Force SAN DIEGO, June 26, 2024 (GLOBE NEWSWIRE) —  Genasys Inc. (NASDAQ: GNSS), the global leader in Protective Communications, today announced an LRAD 950NXT systems order from Damen Schelde Naval Shipbuilding B.V. (Damen) for the German Navy’s new F-126 frigates, the largest shipbuilding project in the history of the German Navy. Damen will outfit four frigates with multiple LRAD 950NXT systems, with an option to outfit two additional frigates. The first shipment is scheduled this September with further shipments in fiscal years 2025 and 2026 “Since its launch two years ago, the 950NXT has quickly become the world’s leading remotely operated, maritime acoustic hailing device (AHD) with six international navies and several superyacht...